November 15, 2021
Watkins advised the lead investor in Cambridge Epigenetix’s, a life sciences
tools and technology company revolutionizing genome sequencing, US$88 million
Series D financing, bringing its total funds raised to date to US$146 million.
Proceeds from the
financing will be used to commercialize Cambridge Epigenetix’s proprietary
genetic and epigenetic sequencing technology, which easily integrates into
existing sequencing platforms to enable more information to be read from DNA.
The Latham team was
led by London corporate partner Mike Turner, with associate Samantha Si.